Angela Gueli

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

Corrado Tarella, Roberto Passera, Michele Magni et al. · Journal of Clinical Oncology · 2010 · 166 citations · Full text

The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy

Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti et al. · American Journal of Hematology · 2013 · 64 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Dlbcl Patients +14

Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma

A. Balbo-Mussetto, S. Cirillo, Riccardo Bruna et al. · Clinical Radiology · 2015 · 37 citations

Engineering, Medical Imaging, Whole-body Mri +9

Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival

Corrado Tarella, Angela Gueli, Federica Delaini et al. · PLoS ONE · 2014 · 26 citations · Full text

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

Simone Ferrero, Luigia Monitillo, Barbara Mantoan et al. · Annals of Hematology · 2013 · 20 citations

Hematological Malignancy, Molecular Relapse, Lymphoid Neoplasia +9